cilostazol has been researched along with Arrhythmias, Cardiac in 8 studies
Arrhythmias, Cardiac: Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous reports demonstrated that cilostazol, a phosphodiesterase 3 inhibitor, affected cellular electrophysiology and reduced episodes of ventricular fibrillation (VF) in patients with Brugada syndrome." | 7.76 | Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine. ( Chattipakorn, N; Chattipakorn, S; Kanlop, N; Shinlapawittayatorn, K; Sungnoon, R; Weerateerangkul, P, 2010) |
| " In the last few years, cilostazol, a phosphodiesterase (PDE) 3 inhibitor, has been tested in the setting of acute coronary syndromes: it exerts not only anti-platelet actions, but also pleiotropic effects, including inhibition on neointimal hyperplasia, therefore preventing both stent restenosis and thrombosis." | 4.88 | Cilostazol and primary-PCI: mirage or good alternative? ( Crea, F; D'Amario, D; Porto, I, 2012) |
| "Previous reports demonstrated that cilostazol, a phosphodiesterase 3 inhibitor, affected cellular electrophysiology and reduced episodes of ventricular fibrillation (VF) in patients with Brugada syndrome." | 3.76 | Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine. ( Chattipakorn, N; Chattipakorn, S; Kanlop, N; Shinlapawittayatorn, K; Sungnoon, R; Weerateerangkul, P, 2010) |
| "Cilostazol is a selective phosphodiesterase 3 (PDE3) inhibitor approved by the Food and Drug Administration for treatment of intermittent claudication." | 2.47 | Effects of cilostazol in the heart. ( Chattipakorn, N; Chattipakorn, S; Kanlop, N, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasegawa, K | 1 |
| Ashihara, T | 1 |
| Kimura, H | 1 |
| Jo, H | 1 |
| Itoh, H | 1 |
| Yamamoto, T | 1 |
| Aizawa, Y | 1 |
| Horie, M | 1 |
| Kwon, BJ | 1 |
| Lee, SH | 1 |
| Kim, DB | 1 |
| Park, HJ | 1 |
| Jang, SW | 1 |
| Ihm, SH | 1 |
| Kim, HY | 1 |
| Seung, KB | 1 |
| Barta, J | 2 |
| Sanganalmath, SK | 2 |
| Kumamoto, H | 2 |
| Takeda, N | 2 |
| Edes, I | 1 |
| Dhalla, NS | 2 |
| Kanlop, N | 2 |
| Shinlapawittayatorn, K | 1 |
| Sungnoon, R | 1 |
| Weerateerangkul, P | 1 |
| Chattipakorn, S | 2 |
| Chattipakorn, N | 2 |
| Porto, I | 1 |
| D'Amario, D | 1 |
| Crea, F | 1 |
| Atarashi, H | 1 |
| Endoh, Y | 1 |
| Saitoh, H | 1 |
| Kishida, H | 1 |
| Hayakawa, H | 1 |
2 reviews available for cilostazol and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Effects of cilostazol in the heart.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cilostazol; Heart Conduction System; Heart Failure; He | 2011 |
Cilostazol and primary-PCI: mirage or good alternative?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Aspirin; Cilostazol; | 2012 |
2 trials available for cilostazol and Arrhythmias, Cardiac
| Article | Year |
|---|---|
A randomized comparison study assessing the impact of cilostazol on the heart rate and arrhythmias by 24-hour ambulatory holter electrocardiographic monitoring after drug-eluting stent implantation for coronary artery disease.
Topics: Arrhythmias, Cardiac; Cilostazol; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting S | 2015 |
Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias.
Topics: Administration, Oral; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Atrial Fibrillation; Bradycardi | 1998 |
4 other studies available for cilostazol and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Long-term pharmacological therapy of Brugada syndrome: is J-wave attenuation a marker of drug efficacy?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; C | 2014 |
Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cilostazol; Coronary Occlusion; Cyclic AMP; D | 2008 |
Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cilostazol; Electric Countershock; Female; He | 2010 |
Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Cilostazol; Disease Models, Animal; Echocardiography; Electrocardiogr | 2008 |